Board Meeting held today on 13th February, 2026 to consider and approve the unaduited standalone financial result for the quarter ended 31st December 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved the standalone unaudited financial results for the quarter and nine months ended 31 December 2025. Total income for Q3 FY26 stood at Rs 14,127.44 lakhs versus Rs 3,337.34 lakhs in Q3 FY25, with net profit at Rs 2,165.57 lakhs versus Rs 347.56 lakhs YoY. For the nine months, net profit rose to Rs 5,133.52 lakhs (vs Rs 749.85 lakhs) and EPS reached Rs 26.27. The figures reflect the merger of Plus Care International Limited into the company effective 25 March 2025, so prior-year numbers are not fully comparable. The statutory auditor issued an unmodified (clean) limited review report. Separately, Director Harshal Bhimashankar Dubli resigned effective 4 February 2026.
Reported growth looks blockbuster on paper, but a large part is driven by the Plus Care merger rather than pure organic expansion, so investors should treat YoY comparisons cautiously. The director exit is a governance item to watch, though financial performance remains strong with double-digit EPS.